Recombinant NRGβ1 was purified as previously described 17. Antibodies specific for p35 (c-19), Cdk2 (M2), cyclin A (H-432), Cdk5 (c-8 and DC-17), ErbB2 (c-18) and ErbB3 (c-17) were purchased from ...

In a newly published study, researchers from the CSIR Institute of Genomics and Integrative Biology and collaborators further explored the potential of Cdk5 targeting as a therapeutic approach for ...

To see whether this system might be affected in sporadic Parkinson's disease in humans, the authors stained ventral midbrain sections with an antibody ... kinase 5 (Cdk5) downregulates ...